Top Qs
Timeline
Chat
Perspective
SCH-50971
Pharmaceutical compound From Wikipedia, the free encyclopedia
Remove ads
SCH-50971 is a histamine H3 receptor agonist which was under development for the treatment of anxiety disorders, gastrointestinal disorders, and migraine but was never marketed.[2][3]
The drug acts as a potent, selective, and high-affinity agonist of the histamine H3 receptor.[4][5] It has negligible affinity for the histamine H1 receptor and other assessed receptors.[4] The drug is also not a histamine H2 receptor antagonist.[4] It has greatly improved selectivity compared to the earlier selective histamine H3 receptor agonist (R)-α-methylhistamine.[4][5] The drug is orally active and shows anti-allergy effects, antimigraine effects, sedative and hypnotic effects, and hypolocomotion in animals.[6][7][1] In terms of chemical structure, it is a cyclized pyrrolidine derivative of histamine.[8][4]
SCH-50971 was under development by Schering-Plough.[2] It reached the discovery or preclinical research stage of development.[3] The development of the drug was discontinued by 2001.[2] SCH-50971 was first described in the scientific literature by 1994.[9][10]
Remove ads
See also
- BP 2.94
- Cipralisant (GT-2331)
- GT-2203 (VUF-5296)
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads